AustralianSuper Pty Ltd lessened its holdings in Solventum Corporation (NYSE:SOLV – Free Report) by 25.4% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 92,985 shares of the company’s stock after selling 31,588 shares during the period. AustralianSuper Pty Ltd owned 0.05% of Solventum worth $7,052,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Rossby Financial LCC bought a new position in shares of Solventum in the first quarter valued at about $25,000. Strengthening Families & Communities LLC grew its stake in Solventum by 376.8% in the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after buying an additional 260 shares during the last quarter. Barrett & Company Inc. raised its holdings in Solventum by 206.2% in the 2nd quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock valued at $30,000 after acquiring an additional 268 shares during the period. IMG Wealth Management Inc. acquired a new stake in Solventum during the second quarter worth approximately $31,000. Finally, Hara Capital LLC bought a new stake in shares of Solventum during the first quarter worth approximately $38,000.
Solventum Stock Up 0.9%
SOLV stock opened at $72.08 on Tuesday. Solventum Corporation has a 52 week low of $60.70 and a 52 week high of $85.92. The business has a 50-day simple moving average of $72.64 and a 200 day simple moving average of $72.24. The company has a quick ratio of 0.86, a current ratio of 1.22 and a debt-to-equity ratio of 2.14. The company has a market cap of $12.50 billion, a PE ratio of 33.37, a price-to-earnings-growth ratio of 2.91 and a beta of 0.50.
Analyst Upgrades and Downgrades
A number of equities analysts have recently weighed in on SOLV shares. Jefferies Financial Group began coverage on Solventum in a research note on Thursday, September 11th. They set a “hold” rating and a $80.00 target price on the stock. Zacks Research raised Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Wall Street Zen cut shares of Solventum from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, September 9th. Morgan Stanley raised shares of Solventum from an “equal weight” rating to an “overweight” rating and raised their price target for the stock from $80.00 to $103.00 in a research report on Tuesday, July 15th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Solventum in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Solventum presently has an average rating of “Hold” and a consensus price target of $84.89.
Get Our Latest Research Report on Solventum
About Solventum
Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.
Featured Stories
- Five stocks we like better than Solventum
- P/E Ratio Calculation: How to Assess Stocks
- Growth Picks: 3 Low-Cost Stocks That Could Double in Value
- What Are Trending Stocks? Trending Stocks Explained
- Are These 3 Beaten-Down Stocks Ready to Rebound?
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Does the Trump-Induced Quantum Stock Rally Have Legs?
Receive News & Ratings for Solventum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solventum and related companies with MarketBeat.com's FREE daily email newsletter.
